类风湿性关节炎
STAT蛋白
基因表达
发病机制
基因
斯达
基因表达谱
微阵列分析技术
微阵列
免疫系统
生物
免疫学
医学
车站3
遗传学
作者
Tineke C. T. M. van der Pouw Kraan,F. van Gaalen,Pia V. Kasperkovitz,Nicolette L. Verbeet,Tom Smeets,Maarten C. Kraan,Mike Fero,Paul‐Peter Tak,T. Huizinga,Elsbet J. Pieterman,Ferdinand C. Breedveld,Ash A. Alizadeh,Cornelis L. Verweij
摘要
Abstract Objective To generate a molecular description of synovial tissue from rheumatoid arthritis (RA) patients that would allow us to unravel novel aspects of pathogenesis and to identify different forms of disease. Methods We applied complementary DNA microarray analysis to profile gene expression, with a focus on immune‐related genes, in affected joint tissues from RA patients and in tissues from osteoarthritis (OA) patients as a control. To validate microarray data, real‐time polymerase chain reaction was performed on genes of interest. Results The gene expression signatures of synovial tissues from RA patients showed considerable variability, resulting in the identification of at least two molecularly distinct forms of RA tissues. One class of tissues revealed abundant expression of clusters of genes indicative of an involvement of the adaptive immune response. Detailed analysis of the expression profile provided evidence for a prominent role of an activated signal transducer and activator of transcription 1 pathway in these tissues. The expression profiles of another group of RA tissues revealed an increased tissue remodeling activity and a low inflammatory gene expression signature. The gene expression pattern in the latter tissues was reminiscent of that observed in the majority of OA tissues. Conclusion The differences in the gene expression profiles provide a unique perspective for distinguishing different pathogenetic RA subsets based on molecular criteria. These data reflect important aspects of molecular variation that are relevant for understanding the biologic dysregulation underlying these subsets of RA. This approach may also help to define homogeneous groups for clinical studies and evaluation of targeted therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI